IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis
The Journal of Allergy and Clinical Immunology, 06/08/2012
Krueger JG et al. – The data suggest that IL–17 is a key “driver” cytokine that activates pathogenic inflammation in subjects with psoriasis. Neutralizing IL–17 with ixekizumab might be a successful therapeutic strategy in psoriasis.